Can Eurofins Viracor’s BKV inSIGHT panel solve a dangerous kidney transplant monitoring blind spot?
Eurofins Viracor launches BKV inSIGHT for BK virus T-cell monitoring, but adoption will depend on validation and treatment-guidance evidence.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3
Natera’s Prospera assay will provide serial molecular graft surveillance in Eledon’s planned Phase 3 tegoprubart study, creating a major test of how diagnostics can strengthen transplant drug development.
Pharma & Biotech
Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
Memo Therapeutics’ Phase 2 data show sustained BK polyomavirus reductions and kidney-biopsy improvement, but a missed primary endpoint leaves its pivotal trial carrying the decisive burden.
Pharma & Biotech
Why Hansa Biopharma’s ConfIdeS trial could reshape kidney transplant desensitization
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.
Pharma & Biotech
How Hansa Biopharma is targeting a transplant blind spot with Imlifidase
Hansa Biopharma AB has submitted a Biologics License Application to the U.S. Food and Drug Administration for imlifidase as a desensitization treatment in highly sensitized adult patients awaiting deceased donor kidney transplants. The submission is supported by the pivotal Phase 3 ConfIdeS trial, and the company is seeking a priority review that could lead to